FDA clears a supplement to a generic buprenorphine and naloxone application

The FDA approved a supplement to abbreviated new drug application ANDA 205022, for buprenorphine hydrochloride with naloxone hydrochloride, held by Lannett, on 14 August 2026. This is a change to an existing generic product rather than a new approval, and the record does not state which change or which formulation - the combination is marketed mainly as a sublingual film or tablet for opioid use disorder.

The reason it belongs on an anaesthetic desk is the patient, not the product. Buprenorphine and naloxone is increasingly common in surgical populations, and the perioperative question it raises has a settled answer that is still not consistently applied: routine preoperative discontinuation has largely been abandoned, because stopping it destabilises the patient and makes postoperative analgesia harder rather than easier. The practical work is planning multimodal and regional analgesia around a continued dose, and involving the prescriber early.

Supply continuity matters here in a way it does not for most drugs, since an interruption for a patient on opioid agonist treatment is a clinical event rather than an inconvenience. That is the whole relevance of an approval like this one: another manufacturer's application staying current is what keeps the medicine on the shelf.

• Do not stop buprenorphine and naloxone routinely before surgery; plan analgesia around it instead.
• Identify these patients at preassessment and involve the usual prescriber before the day of surgery.
• Plan regional and multimodal analgesia early; opioid requirements will be higher and less predictable.
• This is a generic supplement, not a new product or indication, and the formulation is not stated.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.